BRAF mutation detection in indeterminate thyroid cytology specimens: Underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma

Cancer Cytopathology

Volumn 121, Issue 4, 2013, Pages 197-205

  Ohori, N Paul ^a   Singhal, Rashi ^a   Nikiforova, Marina N ^a   Yip, Linwah ^a   Schoedel, Karen E ^a   Coyne, Christopher ^a   McCoy, Kelly L ^a   LeBeau, Shane O ^a   Hodak, Steven P ^a   Carty, Sally E ^a   Nikiforov, Yuri E ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Bethesda classification; BRAF; Fine needle aspiration; Molecular marker; Papillary carcinoma

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADULT; ARTICLE; ATYPIA OF UNDETERMINED SIGNIFICANCE FOLLICULAR LESION OF UNDETERMINED SIGNIFICANCE; B RAF KINASE GENE; BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY; CANCER CLASSIFICATION; CANCER CYTODIAGNOSIS; CONTROLLED STUDY; CYTOLOGY; CYTOPATHOLOGY; DIAGNOSTIC VALUE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FOLLICULAR NEOPLASM SUSPICIOUS FOR FOLLICULAR NEOPLASM; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POSITIVE FOR MALIGNANCY; PRIORITY JOURNAL; SUSPICIOUS FOR MALIGNANCY; THYROID CANCER; THYROID CYTOLOGY; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; ADENOCARCINOMA; CYTODIAGNOSIS; GENETICS; MIDDLE AGED; MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; THYROID GLAND; THYROID TUMOR; BRAF GENE; CANCER DIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; FOLLICULAR CARCINOMA; FOLLOW UP; GENETIC ASSOCIATION; HISTOPATHOLOGY; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADULT; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; CYTODIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; THYROID GLAND; THYROID NEOPLASMS;

MLCS; MLOWN;

EID: 84878407452     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21229     Document Type: Article

References (36)

1. Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration: Experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer (Cancer Cytopathol). 2009;117:195-202.
2. Theoharis CG, Schofield KM, Hammers L, Udelsman R, Chhieng DC. The Bethesda thyroid fine-needle aspiration classification system: Year 1 at an academic institution. Thyroid. 2009;19:1215-1223.
3. Marchevsky AM, Walts AE, Bose S, et al. Evidence-based evaluation of the risks of malignancy predicted by thyroid fine-needle aspiration biopsies. Diagn Cytopathol. 2010;38:252-259.
4. Jo VY, Stelow EB, Dustin SM, Hanley KZ. Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2010;134:450-456.
5. Renshaw AA. Should "atypical follicular cells" in thyroid fineneedle aspirates be subclassified? Cancer (Cancer Cytopathol). 2010;118:186-189.
6. Luu MH, Fischer AH, Pisharodi L, Owens CL. Improved preoperative definitive diagnosis of papillary thyroid carcinoma in FNAs prepared with both ThinPrep and conventional smears compared with FNAs prepared with ThinPrep alone. Cancer (Cancer Cytopathol). 2011;119:68-73.
7. Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: Diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab. 2008;22:955-969.
8. Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011;135:569-577.
9. Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19:1351-1361.
10. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: A prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390-3397.
11. Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria and Explanatory Notes. 1st ed. New York: Springer-Verlag New York, LLC; 2010.
12. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092-2098.
13. Yip L, Nikiforova MN, Carty SE, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009;146:1215-1223.
14. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer (Cancer Cytopathol). 2010;118:17-23.
15. Chiosea S, Nikiforova M, Zuo H, et al. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol. 2009;20:122-126.
16. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36:425-437.
17. Filie AC, Asa SL, Geisinger KR, et al. Utilization of ancillary studies in thyroid fine needle aspirates: A synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36:438-441.
18. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
19. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
20. Jung CK, Kang YG, Bae JS, Lim DJ, Choi YJ, Lee KY. Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Mod Pathol. 2010;23:1201-1208.
21. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: A metaanalysis. Cancer. 2007;110:38-46.
22. Kim T, Roh JH, Park HJ, et al. The frequency of BRAF mutation in very small papillary thyroid carcinomas. Korean J Pathol. 2010;44:308-314.
23. Marchetti I, Lessi F, Mazzanti CM, et al. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid. 2009;19:837-842.
24. Zatelli MC, Trasforini G, Leoni S, et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol. 2009;161:467-473.
25. Kim SW, Lee JI, Kim JW, et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: A large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab. 2010;95:3693-3700.
26. Moses W, Weng J, Sansano I, et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg. 2010;34:2589-2594.
27. Proietti A, Giannini R, Ugolini C, et al. BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features. Thyroid. 2010;20:1263-1270.
28. Adeniran AJ, Theoharis C, Hui P, et al. Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: A prospective study. Thyroid. 2011;21:717-723.
29. Colanta A, Lin O, Tafe L, et al. BRAF mutation analysis of fineneedle aspiration biopsies of papillary thyroid carcinoma: Impact on diagnosis and prognosis. Acta Cytol. 2011;55:563-569.
30. Kang G, Cho EY, Shin JH, Chung JH, Kim JW, Oh YL. Role of BRAFV600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule. Cancer (Cancer Cytopathol). 2012;120:44-51.
31. Kim SK, Hwang TS, Yoo YB, et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab. 2011;96:658-664.
32. Pelizzo MR, Boschin IM, Barollo S, et al. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin Chem Lab Med. 2011;49:325-329.
33. Chang H, Lee H, Yoon SO, Kim H, Kim A, Kim BH. BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma. Hum Pathol. 2012;43:89-95.
34. Marchetti I, Iervasi G, Mazzanti CM, et al. Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: An easy tool to improve the preoperative diagnosis. Thyroid. 2012;22:292-298.
35. Ohori NP, Schoedel KE. Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the bethesda system for reporting thyroid cytopathology: Sources and recommendations. Acta Cytol. 2011;55:492-498.
36. Yip L, Farris C, Kabaker AS, et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab. 2012;97:1905-1912.